Premium
Protein Expression Profiles Corresponding to Histological Changes with Denosumab Treatment in Giant Cell Tumors of Bone
Author(s) -
Suehara Yoshiyuki,
Okubo Taketo,
Kurihara Taisei,
Hayashi Takuo,
Kohsaka Shinji,
Kazuno Saiko,
Sano Kei,
Hasegawa Nobuhiko,
Miura Yoshiki,
Akaike Keisuke,
Kim Youngji,
Takamochi Kazuya,
Takahashi Fumiyuki,
Ueno Takashi,
Kaneko Kazuo,
Saito Tsuyoshi
Publication year - 2019
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201800147
Subject(s) - denosumab , protein expression , giant cell tumor of bone , expression (computer science) , cell , pathology , cancer research , medicine , biology , giant cell , osteoporosis , computer science , genetics , gene , programming language
Purpose Giant cell tumors of bone (GCTBs) are locally aggressive osteolytic bone tumors. Denosumab is a novel and effective therapeutic option for aggressive and recurrent GCTBs. Histologically, the post‐denosumab‐treated samples are characterized by two lesions: a residual stromal cell lesion with a few multinucleated giant cells (SL‐lesion), and a fibro‐osseous lesion (FO‐lesion). Experimental design To clarify the differences in the protein expression between the SL‐lesion and FO‐lesion in GCTB treated with denosumab, comparative proteomic studies are conducted using both lesions (12 pairs of pre‐ and post‐denosumab treatment samples) by isobaric tags for relative and absolute quantification (i‐TRAQ). Results Thirty‐two consistently regulated proteins in the SL‐lesions and 59 consistently regulated proteins in the FO‐lesions are found. Twenty‐one proteins in the SL‐lesion and 48 proteins in the FO‐lesion are independently expressed. These proteins may be involved in the process of the fibro‐osseous reactions by denosumab treatment. In the software program used to establish these profiles, several canonical pathways are identified, including the unfolded protein response as an FO‐lesion specific pathway. Conclusions and clinical relevance It is believed that the identified proteins and the results of the network analysis will provide a better understanding of the effects of denosumab in GCTB.